Hematologic Oncology | Specialty

Dr. DeVita on Chemotherapy in Hodgkin's Lymphoma

November 11th 2013

Vincent T. DeVita, Jr, MD, Lymphoma: Giant of Cancer Care, Yale Cancer Center, discusses the use of chemotherapy for patients with Hodgkin's lymphoma.

Infinity Has High Hopes for PI3K Inhibitor

November 7th 2013

Infinity Pharmaceuticals of Cambridge, Massachusetts, began its efforts to produce innovative cancer treatments 12 years ago.

Drug Shortages Persist in Wake of Surveys

November 6th 2013

Headlines from the June meeting of the American Society of Clinical Oncology (ASCO) in Chicago announced to the general public what oncologists and hematologists have known for more than two years: sporadic shortages of cancer drugs are forcing suboptimal treatment plans for patients, and government efforts have not filled the void.

FDA Approves Frontline Obinutuzumab for CLL

November 1st 2013

The FDA has approved obinutuzumab plus chlorambucil as a first-line treatment for patients with chronic lymphocytic leukemia, based on clinical trial data demonstrating that the combination more than doubled median PFS over the chemotherapy agent alone.

Ponatinib Manufacturer Suspends Distribution

October 31st 2013

Marketing and commercial distribution of ponatinib has been temporarily suspended, following an ongoing FDA investigation that revealed an increased frequency of arterial thrombosis and severe narrowing of the blood vessels.

Side Effect Management With Corticosteroids

October 27th 2013

The Role of Patient Education in Side Effect Management

October 27th 2013

Managing BRAF Inhibitor Associated Skin Toxicity

October 27th 2013

The Nurse's Role in Managing Skin Toxicity

October 27th 2013

Managing mTOR Inhibitor Induced Adverse Events

October 27th 2013

Interdisciplinary Approach to Managing Skin Toxicities

October 27th 2013

Managing Treatment-Related Hand-Foot Skin Reaction

October 27th 2013

Managing BCR-ABL Inhibitor Associated Skin Rash

October 27th 2013

Managing Angiogenesis Inhibitor Related Skin Toxicity

October 27th 2013

Anticipatory Coping in Patients Treated With EGFR Inhibitors

October 27th 2013

Managing EGFR Inhibitor Associated Skin Toxicity

October 27th 2013

Unique Considerations With TKIs for Chronic Myelogenous Leukemia

October 25th 2013

At the recent NCCN 8th Annual Congress on Hematologic Malignancies, Michael Millenson, MD, Fox Chase Cancer Center, discussed considerations in selecting second- and third-generation tyrosine-kinase inhibitors for the management of chronic myelogenous leukemia

Novel B-Cell Receptor Signaling Inhibitors Show Promise

October 23rd 2013

Drugs targeting B-cell receptor signaling pathways are improving outcomes for patients with B-cell lymphomas; these novel agents include idelalisib and ibrutinib, and are considered a breakthrough for CLL and other B-cell lymphomas.

Late-Stage Ponatinib Study Discontinued

October 18th 2013

The phase III EPIC trial that was exploring ponatinib in untreated patients with chronic myeloid leukemia has been discontinued following a high occurrence of arterial thrombotic events.

Positive Idelalisib Data Ends Late-Stage CLL Trial

October 10th 2013

A phase III study of the PI3K-delta inhibitor idelalisib in combination with rituximab has been stopped early following a positive interim analysis.